These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 8561860)
1. Correlation of p53 immunoreactivity and sequencing in patients with glioma. Kyritsis AP; Xu R; Bondy ML; Levin VA; Bruner JM Mol Carcinog; 1996 Jan; 15(1):1-4. PubMed ID: 8561860 [TBL] [Abstract][Full Text] [Related]
2. Absence of p53 autoantibodies in sera from glioma patients. Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045 [TBL] [Abstract][Full Text] [Related]
3. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Rasheed BK; Stenzel TT; McLendon RE; Parsons R; Friedman AH; Friedman HS; Bigner DD; Bigner SH Cancer Res; 1997 Oct; 57(19):4187-90. PubMed ID: 9331072 [TBL] [Abstract][Full Text] [Related]
4. p53 mutation and protein alteration in 50 gliomas. Retrospective study by DNA-sequencing techniques and immunohistochemistry. von Eckardstein K; Gries H; Bolik E; Cervós-Navarro J; Tschairkin IN; Patt S Histol Histopathol; 1997 Jul; 12(3):611-6. PubMed ID: 9225141 [TBL] [Abstract][Full Text] [Related]
5. Mutations of the p53 gene in gliomas from Malay patients. Jafri A; Aziz MY; Ros S; Nizam I Med J Malaysia; 2003 Jun; 58(2):236-42. PubMed ID: 14569744 [TBL] [Abstract][Full Text] [Related]
6. p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas. Jin W; Xu X; Yang T; Hua Z Chin Med J (Engl); 2000 Jul; 113(7):662-6. PubMed ID: 11776043 [TBL] [Abstract][Full Text] [Related]
7. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53 immunoreactivity in patients with glioma. Kyritsis AP; Bondy ML; Hess KR; Cunningham JE; Zhu D; Amos CJ; Yung WK; Levin VA; Bruner JM Clin Cancer Res; 1995 Dec; 1(12):1617-22. PubMed ID: 9815964 [TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of the functional p53 status in glioma cells. Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541 [TBL] [Abstract][Full Text] [Related]
10. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment. Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349 [TBL] [Abstract][Full Text] [Related]
11. Ethnicity delineates different genetic pathways in malignant glioma. Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811 [TBL] [Abstract][Full Text] [Related]
12. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Tada M; Iggo RD; Waridel F; Nozaki M; Matsumoto R; Sawamura Y; Shinohe Y; Ikeda J; Abe H Mol Carcinog; 1997 Mar; 18(3):171-6. PubMed ID: 9115587 [TBL] [Abstract][Full Text] [Related]
13. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. Ren ZP; Olofsson T; Qu M; Hesselager G; Soussi T; Kalimo H; Smits A; Nistér M J Neuropathol Exp Neurol; 2007 Oct; 66(10):944-54. PubMed ID: 17917588 [TBL] [Abstract][Full Text] [Related]
14. Distribution of p53 alterations in a case of gliomatosis cerebri. Mawrin C; Lins H; Kirches E; Schildhaus HU; Scherlach C; Kanakis D; Dietzmann K Hum Pathol; 2003 Jan; 34(1):102-6. PubMed ID: 12605375 [TBL] [Abstract][Full Text] [Related]
15. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715 [TBL] [Abstract][Full Text] [Related]
16. Mutations of the p16 gene in gliomas. Kyritsis AP; Zhang B; Zhang W; Xiao M; Takeshima H; Bondy ML; Cunningham JE; Levin VA; Bruner J Oncogene; 1996 Jan; 12(1):63-7. PubMed ID: 8552400 [TBL] [Abstract][Full Text] [Related]
17. Role of gemistocytes in astrocytoma progression. Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164 [TBL] [Abstract][Full Text] [Related]
18. TP53 promoter methylation in human gliomas. Amatya VJ; Naumann U; Weller M; Ohgaki H Acta Neuropathol; 2005 Aug; 110(2):178-84. PubMed ID: 16025287 [TBL] [Abstract][Full Text] [Related]
19. p53 alterations in chemically induced hamster cheek-pouch lesions. Gimenez-Conti IB; LaBate M; Liu F; Osterndorff E Mol Carcinog; 1996 Aug; 16(4):197-202. PubMed ID: 8784462 [TBL] [Abstract][Full Text] [Related]
20. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Sidransky D; Mikkelsen T; Schwechheimer K; Rosenblum ML; Cavanee W; Vogelstein B Nature; 1992 Feb; 355(6363):846-7. PubMed ID: 1311419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]